Further studies showed that IL-10 promoter polymorphisms were correlated with tumor progression and clinical outcomes in a number of cancers, such as breast cancer, squamous cell carcinoma (SCC) after renal transplantation, and non-small cell lung cancer (NSCLC) (8). Here, IL10 is linked to non-small cell lung carcinoma.